세계의 결핵 치료제 시장 보고서(2025년)

Tuberculosis Therapeutics Global Market Report 2025

US $ 4,490 ￦ 6,265,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,056,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,846,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

결핵 치료제 시장 규모는 향후 수년간 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 6.32%의 연평균 복합 성장률(CAGR)로 25억 7,000만 달러에 달할 것으로 예측됩니다. 예측 기간 중 예상되는 성장의 원동력은 의료 인프라에 대한 투자 증가, 인식 제고 및 교육 활동 강화, 연구개발 투자 확대, 다양한 항결핵제 제품 승인 증가, 연구 자금 확대, 노인 인구 증가 등입니다. 이 기간 중 예상되는 주요 동향으로는 의약품 개발의 진보, 맞춤형 의료의 부상, 병용요법, 디지털 헬스 솔루션의 통합, AI와 머신러닝의 신약개발 활용 등을 들 수 있습니다.

결핵과 HIV 동시 감염률 증가는 향후 수년간 결핵 치료제 시장의 성장을 가속할 것으로 예측됩니다. 결핵-HIV 동시 감염은 결핵과 인체면역결핍바이러스(HIV)에 동시에 감염된 사람을 말합니다. 동시 감염 증가는 고위험군 집단에서 이러한 전염병의 세계적 중첩과 함께 결핵에 대한 감수성을 높이는 HIV에 의한 면역체계 억제에 기인합니다. 결핵 치료제는 HIV와 관련된 면역 억제를 완화하면서 결핵과 싸우는 표적 치료제를 제공함으로써 환자의 예후를 개선하고 이중 질병 부담을 줄임으로써 이러한 중복 감염에 대응하는 데 중요한 역할을 하고 있습니다. 예를 들어 2023년 10월 gov.uk가 발표한 자료에 따르면 영국에서는 2022년에 3,805건의 신규 HIV 진단이 기록되며, 2021년에 보고된 3,118건보다 22% 증가했습니다. 이러한 공감염률 증가는 결핵 치료제에 대한 수요를 크게 촉진하고 있습니다.

결핵 치료제 시장의 주요 기업은 치료 효과를 높이고, 치료 기간을 단축하고, 약제 내성 결핵균에 대응하기 위해 병용 요법과 같은 발전에 초점을 맞추었습니다. 병용요법은 치료 효과를 높이고 내성을 최소화하며 환자의 전반적인 치료 결과를 개선하기 위해 두 가지 이상의 서로 다른 계열의 약물을 사용하는 것을 말합니다. 예를 들어 존슨앤드존슨은 2024년 7월 미국 FDA와 유럽위원회로부터 SIRTURO(베다퀼린)를 승인받아 40여년만에 다제내성 결핵(MDR-TB)을 위해 특별히 고안된 약물로 획기적인 진전을 이루었습니다. SIRTURO는 결핵균의 에너지 생산에 중요한 ATP 합성효소를 표적으로 삼음으로써 강력한 표적 치료 옵션을 제공합니다. 병용요법에 통합하여 치료 효과를 높이고, 치료 기간을 단축하며, 환자의 치료 순응도를 높일 수 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 결핵 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 용도 산업의 분석
• 세계의 결핵 치료제 시장 : 성장률 분석
• 세계의 결핵 치료제 시장 실적 : 규모와 성장, 2019-2024
• 세계의 결핵 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 결핵 치료제 TAM(Total Addressable Market)

제6장 시장 세분화

• 세계의 결핵 치료제 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 활동성 결핵(TB)
• 잠복 결핵(TB)
• 세계의 결핵 치료제 시장 : 제품 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Isoniazid
• Rifampin
• Pyrazinamide
• 히드라진 유도체
• 기타 항결핵약
• Ethambutol
• 세계의 결핵 치료제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 비경구
• 기타 투여 경로
• 세계의 결핵 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타 유통 채널
• 세계의 결핵 치료제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 클리닉
• 외래 수술 센터
• 기타 최종사용자
• 세계의 결핵 치료제 시장, 활동성 결핵(TB)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 제1 선택약(Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
• 제2 선택약(Fluoroquinolones, Aminoglycosides)
• 병용요법
• 약제 내성 결핵 치료(MDR-TB, XDR-TB)
• 세계의 결핵 치료제 시장, 잠복 결핵(TB)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Isoniazid Prophylaxis
• Rifampicin-Based Regimens
• Rifapentine-Based Regimens
• 병용 예방 요법

제7장 지역별·국가별 분석

• 세계의 결핵 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 결핵 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 결핵 치료제 시장 : 경쟁 구도
• 결핵 치료제 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 대기업과 혁신적 기업

• Bayer AG
• Sanofi S.A.
• Novartis AG
• GlaxoSmithKline plc
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Macleods Pharmaceuticals Ltd.
• Cipla Limited
• Hikma Pharmaceuticals plc
• Lupin Limited
• Alkem Laboratories Limited
• Emcure Pharmaceuticals Limited
• Otsuka Pharmaceutical Co. Ltd.
• Sequella Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 결핵 치료제 시장 2029 : 새로운 기회를 제공하는 국가
• 결핵 치료제 시장 2029 : 새로운 기회를 제공하는 부문
• 결핵 치료제 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁의 전략

제36장 부록

KSA

영문 목차

영문목차

Tuberculosis therapeutics encompass pharmaceutical treatments aimed at preventing and curing tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. These treatments focus on eradicating the bacteria, reducing transmission, and improving outcomes for patients, particularly those with drug-resistant strains.

The primary types of tuberculosis therapeutics are active tuberculosis (TB) and latent tuberculosis (TB). Active tuberculosis is a contagious bacterial infection that primarily affects the lungs, leading to symptoms such as persistent cough, fever, and weight loss. Available product types include isoniazid, rifampin, pyrazinamide, hydrazine derivatives, miscellaneous anti-tubercular drugs, and ethambutol. The treatments are administered via various routes, such as oral, parenteral, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The tuberculosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides tuberculosis therapeutics market statistics, including the tuberculosis therapeutics industry global market size, regional shares, competitors with the tuberculosis therapeutics market share, detailed tuberculosis therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the tuberculosis therapeutics industry. This tuberculosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tuberculosis therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.58%. The growth during the historical period can be attributed to the increasing incidence of tuberculosis, the rising adoption of tuberculosis therapeutics, greater awareness of tuberculosis (TB), the growing prevalence of XDR-TB, and the increasing cases of drug-resistant tuberculosis.

The tuberculosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.32%. The anticipated growth in the forecast period is driven by increased investments in healthcare infrastructure, heightened awareness and education efforts, greater investment in research and development, an increase in product approvals for various anti-TB agents, expanded research funding, and a growing geriatric population. Key trends expected during this period include advancements in drug development, the rise of personalized medicine, combination therapies, integration of digital health solutions, and the use of AI and machine learning in drug discovery.

The increasing rates of TB-HIV co-infections are expected to drive the growth of the tuberculosis therapeutics market in the coming years. TB-HIV co-infection refers to individuals simultaneously infected with tuberculosis (TB) and human immunodeficiency virus (HIV). The rise in co-infections is attributed to the immune system suppression caused by HIV, which increases susceptibility to TB, along with the global overlap of these epidemics in high-risk populations. Tuberculosis therapeutics play a crucial role in addressing these co-infections by providing targeted treatments that combat TB while mitigating HIV-related immune suppression, thereby improving patient outcomes and alleviating the dual disease burden. For example, in October 2023, data from gov.uk indicated that England recorded 3,805 new HIV diagnoses in 2022, reflecting a 22% increase from the 3,118 cases reported in 2021. Such rising co-infection rates are significantly fueling the demand for tuberculosis therapeutics.

Leading companies in the tuberculosis therapeutics market are focusing on advancements such as combination therapies to enhance treatment effectiveness, shorten therapy durations, and address drug-resistant tuberculosis strains. Combination therapy utilizes two or more drugs from different classes to boost treatment efficacy, minimize resistance, and improve overall patient outcomes. For instance, in July 2024, Johnson & Johnson achieved a breakthrough with the approval of SIRTURO (bedaquiline) by the U.S. FDA and the European Commission. SIRTURO is the first drug in over 40 years specifically designed for multidrug-resistant tuberculosis (MDR-TB). By targeting the ATP synthase enzyme critical for TB bacteria's energy production, SIRTURO offers a targeted and potent treatment option. When incorporated into combination therapies, it enhances regimen efficacy, reduces treatment timelines, and promotes better patient adherence.

In May 2024, BioVersys AG, a Swiss biotechnology company, entered into a strategic partnership with GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for tuberculosis treatment. This collaboration aims to advance innovative therapeutic solutions for TB. GSK plc, a UK-based pharmaceutical company, is known for its contributions to developing and manufacturing groundbreaking medicines, including treatments for tuberculosis.

Major players in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.

North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tuberculosis therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tuberculosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tuberculosis therapeutics market consists of sales of combination therapies, vaccines, supportive therapies, biologics, and newer drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tuberculosis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tuberculosis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tuberculosis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tuberculosis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Active Tuberculosis (TB); Latent Tuberculosis (TB)
• 2) By Product Type: Isoniazid; Rifampin; Pyrazinamide; Hydrazine derivatives; Miscellaneous anti-tubercular drugs; Ethambutol
• 3) By Route of Administration: Oral; Parenteral; Other route of administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
• Subsegments:
• 1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol); Second-Line Drugs (Fluoroquinolones, Aminoglycosides); Combination Therapies; Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
• 2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis; Rifampicin-Based Regimens; Rifapentine-Based Regimens; Combination Prophylactic Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tuberculosis Therapeutics Market Characteristics

3. Tuberculosis Therapeutics Market Trends And Strategies

4. Tuberculosis Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Tuberculosis Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tuberculosis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tuberculosis Therapeutics Market Growth Rate Analysis
• 5.4. Global Tuberculosis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tuberculosis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tuberculosis Therapeutics Total Addressable Market (TAM)

6. Tuberculosis Therapeutics Market Segmentation

• 6.1. Global Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Active Tuberculosis (TB)
• Latent Tuberculosis (TB)
• 6.2. Global Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Isoniazid
• Rifampin
• Pyrazinamide
• Hydrazine Derivatives
• Miscellaneous Anti-Tubercular Drugs
• Ethambutol
• 6.3. Global Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route of Administration
• 6.4. Global Tuberculosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Tuberculosis Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Other End-Users
• 6.6. Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Active Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
• Second-Line Drugs (Fluoroquinolones, Aminoglycosides)
• Combination Therapies
• Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
• 6.7. Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Latent Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Isoniazid Prophylaxis
• Rifampicin-Based Regimens
• Rifapentine-Based Regimens
• Combination Prophylactic Therapies

7. Tuberculosis Therapeutics Market Regional And Country Analysis

• 7.1. Global Tuberculosis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tuberculosis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tuberculosis Therapeutics Market

• 8.1. Asia-Pacific Tuberculosis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tuberculosis Therapeutics Market

• 9.1. China Tuberculosis Therapeutics Market Overview
• 9.2. China Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tuberculosis Therapeutics Market

• 10.1. India Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tuberculosis Therapeutics Market

• 11.1. Japan Tuberculosis Therapeutics Market Overview
• 11.2. Japan Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tuberculosis Therapeutics Market

• 12.1. Australia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tuberculosis Therapeutics Market

• 13.1. Indonesia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tuberculosis Therapeutics Market

• 14.1. South Korea Tuberculosis Therapeutics Market Overview
• 14.2. South Korea Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tuberculosis Therapeutics Market

• 15.1. Western Europe Tuberculosis Therapeutics Market Overview
• 15.2. Western Europe Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tuberculosis Therapeutics Market

• 16.1. UK Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tuberculosis Therapeutics Market

• 17.1. Germany Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tuberculosis Therapeutics Market

• 18.1. France Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tuberculosis Therapeutics Market

• 19.1. Italy Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tuberculosis Therapeutics Market

• 20.1. Spain Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tuberculosis Therapeutics Market

• 21.1. Eastern Europe Tuberculosis Therapeutics Market Overview
• 21.2. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tuberculosis Therapeutics Market

• 22.1. Russia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tuberculosis Therapeutics Market

• 23.1. North America Tuberculosis Therapeutics Market Overview
• 23.2. North America Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tuberculosis Therapeutics Market

• 24.1. USA Tuberculosis Therapeutics Market Overview
• 24.2. USA Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tuberculosis Therapeutics Market

• 25.1. Canada Tuberculosis Therapeutics Market Overview
• 25.2. Canada Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tuberculosis Therapeutics Market

• 26.1. South America Tuberculosis Therapeutics Market Overview
• 26.2. South America Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tuberculosis Therapeutics Market

• 27.1. Brazil Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tuberculosis Therapeutics Market

• 28.1. Middle East Tuberculosis Therapeutics Market Overview
• 28.2. Middle East Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tuberculosis Therapeutics Market

• 29.1. Africa Tuberculosis Therapeutics Market Overview
• 29.2. Africa Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tuberculosis Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Tuberculosis Therapeutics Market Competitive Landscape
• 30.2. Tuberculosis Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Tuberculosis Therapeutics Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc
• 31.5. Viatris Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Astellas Pharma Inc.
• 31.8. Macleods Pharmaceuticals Ltd.
• 31.9. Cipla Limited
• 31.10. Hikma Pharmaceuticals plc
• 31.11. Lupin Limited
• 31.12. Alkem Laboratories Limited
• 31.13. Emcure Pharmaceuticals Limited
• 31.14. Otsuka Pharmaceutical Co. Ltd.
• 31.15. Sequella Inc.

32. Global Tuberculosis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tuberculosis Therapeutics Market

34. Recent Developments In The Tuberculosis Therapeutics Market

35. Tuberculosis Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Tuberculosis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tuberculosis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tuberculosis Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료